Plus Therapeutics Inc (NASDAQ: PSTV) kicked off on Monday, down -3.39% from the previous trading day, before settling in for the closing price of $1.18. Over the past 52 weeks, PSTV has traded in a range of $0.24-$2.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 474.41% over the last five years. While this was happening, its average annual earnings per share was recorded 56.01%. With a float of $11.48 million, this company’s outstanding shares have now reached $11.79 million.
The firm has a total of 20 workers. Let’s measure their productivity. In terms of profitability, gross margin is 26.42%, operating margin of -343.29%, and the pretax margin is -301.83%.
Plus Therapeutics Inc (PSTV) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Plus Therapeutics Inc is 2.55%, while institutional ownership is 16.02%. The most recent insider transaction that took place on Sep 13 ’24, was worth 5,996. In this transaction Director of this company bought 4,000 shares at a rate of $1.50, taking the stock ownership to the 15,188 shares. Before that another transaction happened on Sep 12 ’24, when Company’s Director bought 6,285 for $1.35, making the entire transaction worth $8,512. This insider now owns 11,188 shares in total.
Plus Therapeutics Inc (PSTV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 56.01% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 33.56% during the next five years compared to 68.20% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Take a look at Plus Therapeutics Inc’s (PSTV) current performance indicators. Last quarter, stock had a quick ratio of 0.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.24, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Analysing the last 5-days average volume posted by the [Plus Therapeutics Inc, PSTV], we can find that recorded value of 82.13 million was better than the volume posted last year of 16.8 million. As of the previous 9 days, the stock’s Stochastic %D was 46.73%. Additionally, its Average True Range was 0.36.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 43.48%, which indicates a significant increase from 41.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 765.29% in the past 14 days, which was higher than the 328.48% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0893, while its 200-day Moving Average is $1.3838. Now, the first resistance to watch is $1.4233. This is followed by the second major resistance level at $1.7067. The third major resistance level sits at $1.9133. If the price goes on to break the first support level at $0.9333, it is likely to go to the next support level at $0.7267. Should the price break the second support level, the third support level stands at $0.4433.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
The company with the Market Capitalisation of 13.43 million has total of 5,896K Shares Outstanding. Its annual sales at the moment are 4,910 K in contrast with the sum of -13,320 K annual income. Company’s last quarter sales were recorded 1,460 K and last quarter income was -2,870 K.
